RxDoctor Payments Data

Joan Galang

Primary Care · Las Vegas, NVNPI 1407204035

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 33.2% of the total. 2025 is the largest year on record at $164, 6.5 times the $25 reported in 2022. That places this record below the midpoint for primary care clinicians in NV, where the typical reported total is $343.

$343in general payments, 2019–2025

Across 19 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$114
  • Amgen$53
  • Exact Sciences$49
  • Astellas Pharma US Inc$29
  • Pfizer$23
  • GSK$16
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$33197%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$343 in reported general payments places this provider in the 50th percentile of 81 primary care providers in Nevada.

See all primary care providers in Nevada

Medicare billing

Part B allowed, 2024
$20,254
Medicare patients
40
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$22,882
JardianceEmpagliflozin15$21,767
OzempicSemaglutide19$18,763
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen141$6,788
Breo ElliptaFluticasone/Vilanterol16$6,653
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$4,802
SymbicortBudesonide/Formoterol Fumarate13$3,057
Doxepin Hcl12$2,589
Albuterol Sulfate HfaAlbuterol Sulfate81$2,044
Gabapentin100$1,682
Lidocaine16$1,510
Trazodone Hcl25$1,175
Atorvastatin Calcium143$1,066
Alprazolam167$622
Ibuprofen36$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$114$22,88218 claims
Novo NordiskOzempic$14$18,76319 claims
GSKBreo Ellipta$16$6,65316 claims
AstraZenecaSymbicort$15$3,05713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 81 primary care providers in Nevada.

Other primary care in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →